908 Devices and Bio-Techne Announce Joint Collaboration
04 5월 2021 - 8:00PM
Business Wire
908 Devices (NASDAQ: MASS) and Bio-Techne Corporation (NASDAQ:
TECH) today announced a joint collaboration to develop an extended
workflow solution for protein characterization. Bio-Techne, a
global life sciences company providing innovative tools and
bioactive reagents for the research and clinical diagnostic
communities, and owner of the leading ProteinSimple branded protein
analysis portfolio of products, will pair its Maurice icIEF
separation instrument with 908 Devices’ ZipChip device to deliver a
seamless workflow for deeper protein characterization. Maurice and
the iCE technology are the gold standard in protein
characterization, providing absorbance and native fluorescence
icIEF detection as well as CE-SDS, saving significant development
time and reducing the time to commercialization.
908 Devices, a pioneer of purpose-built handheld and desktop
mass spec devices for chemical and biomolecular analysis, enables
high-resolution separation and mass spec sample introduction with
its plug-and-play open access platform, ZipChip, which directly
integrates electrospray ionization with mass spectrometry. The
ZipChip integrates with Thermo Fisher, Sciex, and Bruker mass
spectrometers and leverages Capillary Electrophoresis (CE) and
electrospray ionization technology in order to minimize sample prep
burden, perform high-resolution separations and directly introduce
samples into a mass spec instrument.
Maurice paired with 908 Devices’ ZipChip allows in-depth
characterization of biotherapeutics on an intact and near-native
level. This workflow solution will increase scientists’ drug
development efficiency through additional rapid, high-resolution
separation techniques coupled with mass spectrometry
identification.
“By partnering with Bio-Techne and leveraging their market
leading Maurice icIEF platform with our ZipChip device, we are
together extending the workflow for customers conducting detailed
protein characterization of charge variants,” said Dr. Kevin J.
Knopp, CEO and co-founder of 908 Devices. “This collaboration helps
advance our reach into the biopharmaceutical market.”
“We are very excited to collaborate with 908 Devices to provide
an integrated workflow that enables fraction analysis for our
Maurice users. Analyzing protein charge isoforms is a critical
requirement and this enhanced capability using Maurice with the
ZipChip and MS will provide a deeper understanding of a molecule
through the various stages of development,” stated Dave Eansor,
President of Bio-Techne’s Protein Sciences Segment. “Our iCE
technology has been the gold standard in protein charge
characterization for more than 20 years and this collaboration will
provide additional value to the iCE community.”
About 908 Devices
908 Devices (NASDAQ:MASS) is democratizing laboratory mass
spectrometry with its simple handheld and desktop devices,
addressing critical-to-life applications. The Company’s devices are
used at the point-of-need to interrogate unknown and invisible
materials and provide quick, actionable answers to directly address
some of the most critical problems in life sciences research,
bioprocessing, pharma / biopharma, forensics and adjacent markets.
The Company is headquartered in the heart of Boston, where it
designs and manufactures innovative products that bring together
the power of mass spectrometry, microfluidic separations, software
automation, and machine learning.
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences
company providing innovative tools and bioactive reagents for the
research and clinical diagnostic communities. Bio-Techne products
assist scientific investigations into biological processes and the
nature and progress of specific diseases. They aid in drug
discovery efforts and provide the means for accurate clinical tests
and diagnoses. With thousands of products in its portfolio,
Bio-Techne generated approximately $739 million in net sales in
fiscal 2020 and has over 2,500 employees worldwide. For more
information on Bio-Techne and its brands, please visit
www.bio-techne.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210504005140/en/
For 908 Devices Marketing Contact: Emily Fang PAN Communications
for 908 Devices 908devices@pancomm.com Investor Relations Contact:
Carrie Mendivil IR@908devices.com For Bio-Techne Corporation
Investor Relations Contact: David Clair, Senior Director, Investor
Relations and Corporate Development david.clair@bio-techne.com
612-656-4416
908 Devices (NASDAQ:MASS)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
908 Devices (NASDAQ:MASS)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024